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Abstract
MicroRNA (miRNA) expression was assessed in human cerebral cortical gray matter (GM) and
white matter (WM) in order to provide the first insights into the difference between GM and WM
miRNA repertoires across a range of Alzheimer's disease (AD) pathology. RNA was isolated
separately from GM and WM portions of superior and middle temporal cerebral cortex (N = 10
elderly females, postmortem interval < 4 h). miRNA profiling experiments were performed using
state-of-the-art Exiqon© LNA-microarrays. A subset of miRNAs that appeared to be strongly
expressed according to the microarrays did not appear to be conventional miRNAs according to
Northern blot analyses. Some well-characterized miRNAs were substantially enriched in WM as
expected. However, most of the miRNA expression variability that correlated with the presence of
early AD-related pathology was seen in GM. We confirm that downregulation of a set of miRNAs
in GM (including several miR-15/107 genes and miR-29 paralogs) correlated strongly with the
density of diffuse amyloid plaques detected in adjacent tissue. A few miRNAs were differentially
expressed in WM, including miR-212 that is downregulated in AD and miR-424 which is
upregulated in AD. The expression of certain miRNAs correlates with other miRNAs across
different cases, and particular subsets of miRNAs are coordinately expressed in relation to AD-
related pathology. These data support the hypothesis that patterns of miRNA expression in cortical
GM may contribute to AD pathogenetically, because the aggregate change in miRNA expression
observed early in the disease would be predicted to cause profound changes in gene expression.
Introduction
MicroRNAs (miRNAs) are small non-coding RNAs that participate in gene expression
regulation, mostly at the level of altering mRNA translation. In mammalian brain, miRNAs
have been implicated in many fundamental functions including neurodevelopment,
plasticity, and apoptosis (see reviews [12,33]). Dysregulation of miRNAs has previously
been reported in multiple diseases, including Alzheimer's disease (AD) [6,11,16,24,27,35].
Research on the role(s) of miRNAs in AD must include the evaluation of human material,
because the disease is essentially human-specific. One of the key experimental paradigms
for evaluating human brain miRNAs involves gene expression profiling. These experiments
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may entail high-throughput assessment of the levels of multiple miRNAs across different
tissue samples. In human brain miRNA expression profiling, technical details are critically
important. For example, it is important to know clinical details of the human subjects, tissue
sampling methods, pathological evaluation of adjacent tissue, RNA isolation methods used,
miRNA profiling platform, and downstream data analyses.
Another important technical factor in brain miRNA expression profiling relates to the
heterogeneity of the human cerebral cortex [36]. The peripheral ∼4 mm thick cortical cell
layer (“gray matter”) overlies a deeper zone (“white matter”) that is traversed by myelinated
axons. In terms of cell composition, gray matter comprises mostly neurons, astrocytes,
endothelial cells, microglia, and relatively few oligodendrocytes. By contrast, white matter
has a greater concentration of oligodendrocytes with markedly lower densities of neurons or
blood vessels. Tissue sampling protocols that do not segregate white matter from gray
matter will have increased variability that reflects differently sampled cell populations in
addition to variance that is due to intrinsic factors (for example, disease state). It is a
practical fact that individual samples of “cerebral cortex” can have dramatically different
proportions of gray matter, white matter, and meningeal tissues.
Neuropathological hallmark lesions of AD—neuritic amyloid plaques (NPs) and
neurofibrillary tangles (NFTs) [1]—are predominantly found in gray matter. Our prior work
in AD miRNA profiling assessed RNA from gray matter exclusively [35] although we found
differences in miRNA repertoires in a focused sampling of gray and white matter [36]. It has
been suggested that white matter perturbations, and changes in axon myelination, could be
fundamentally important to AD pathogenesis [3]. There have also been a number of
miRNAs recently shown to be enriched in white matter and/or oligodendrocytes [8,15,38],
and there have been miRNAs newly annotated since our prior study. For these reasons, we
assessed separately the miRNA repertoire in cerebral cortical gray and white matter across a
spectrum of early AD pathology, using state-of-the-art locked nucleic acid (LNA)
microarrays.
Materials and methods
RNA isolation from a human cerebral cortex
Cases were selected on the basis of representing the spectrum of early progression of AD
pathology, and of their being available more recently than our prior study [36] on miRNAs
in AD brain. Premortem clinical evaluations and pathological assessments were as described
previously [21,31,36]. The inclusion criteria that were applied: postmortem interval (PMI) <
4 h; no argyrophilic grains; no cortical Lewy bodies (LB); no evidence of frontotemporal
dementia; no cancer in the brain parenchyma; and no large infarctions in the brain, or
microinfarcts found within 3 cm of the brain tissue samples. These neuropathological
confounds were assessed using standard neuropathological procedures as described in detail
elsewhere [21].
RNA was isolated as previously described in detail [35,36]. RNA was extracted from snap-
frozen brain tissue in the superior and middle temporal gyri (SMT; Brodmann Areas 21/22)
from the UK ADC under a University of Kentucky IRB protocol. All biochemical analyses
were performed blind with respect to patient information. Briefly, prior to RNA extraction,
gray matter was dissected away from white matter and meninges and large blood vessels
were removed. Tissue (1–3 g) that had been snap-frozen in liquid nitrogen and then
transferred to a −80°C freezer was thawed in isotonic lysis buffer with RNAsin (Promega,
Madison, WI; 250 U/ml) and complete protease inhibitor pills (Roche, Basel, Switzerland).
Trizol LS (Invitrogen, Carlsbad, CA) was used according to the manufacturer's instructions,
except for an additional overnight −20°C precipitation step during isopropanol precipitation.
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RNA quality was confirmed using A260/A280 readings and also the Agilent Bioanalyzer for
RNA Integrity Number (RIN).
Most aspects of pathological assessments were as described in detail previously [17,21].
Briefly, sections were obtained from SMT (immediately adjacent to the tissues sampled for
RNA studies), immersion-fixed in formalin and evaluated for AD-type pathology using
conventional methods [18]. Amyloid plaques were separated into DPs (plaques without
neurites) and NPs (plaques with degenerating neurites) in each region as described
previously [21]. An arithmetic mean was calculated from the count of the five most involved
fields for DPs (number of DPs per 2.35 mm2), NPs (number of NPs per 2.35 mm2), and
NFTs (number of NFTs per 0.586 mm2) for each region.
Patient characteristics, along with pathological lesion counts in the same cases, are shown in
Table 1. Cases 3, 4, 5, 6, 8, and 9 were evaluated separately in a different study that
involved RT-qPCR [23] but none of these cases has ever been evaluated previously using a
microarray or any other high-throughput profiling method.
Microarray methods
The quality of the total RNA was verified by an Agilent 2100 Bioanalyzer profile. 1 μg total
RNA from sample and reference was labeled with Hy3™ and Hy5™ fluorescent label,
respectively, using the miRCURY™ LNA Array power labeling kit (Exiqon, Denmark)
following the procedure described by the manufacturer. The Hy3™-labeled samples and a
Hy5™-labeled reference RNA samples (hereafter referred as Cy3 and Cy5) were mixed
pair-wise and hybridized to the miRCURY™ LNA array version 11.0 (Exiqon, Denmark),
which contains capture probes targeting all miRNAs for human, mouse or rat registered in
the miRBASE version 14.0 at the Sanger Institute. The hybridization was performed
according to the miRCURY™ LNA array manual using a Tecan HS4800 hybridization
station. After hybridization the microarray slides were scanned and stored in an ozone-free
environment (ozone level below 2.0 ppb) to prevent potential bleaching of the fluorescent
dyes. The miRCURY™ LNA array microarray slides were scanned using the Agilent
G2565BA Microarray Scanner System (Agilent Technologies, Inc., USA) and the image
analysis was carried out using the ImaGene 8.0 software (BioDiscovery, Inc., USA). The
quantified signals were background corrected (Normexp with offset value 10 as described
previously by Ritchie et al. [30]) and normalized using the global Lowess (LOcally
WEighted Scatterplot Smoothing) regression algorithm.
Northern blots on selected miRNAs
Northern blots were performed as described previously [35].
Data analyses
Data were obtained and normalized as above and exported to a Microsoft Excel™
spreadsheet that served as the basis for additional analyses. The first level of analyses was
performed on the “single-color” raw data obtained from each data point that expressed the
absolute expression values for each miRNA. This was used to obtain hierarchical clustering
based on miRNA expression. Data were converted to a .txt file and imported to Partek
Genomics Suite™ software. Hierarchical clustering was performed using both Euclidean
and Pearson coefficient-based algorithms to demonstrate how cases clustered based on
miRNA expression. Next, we focused on the 170 miRNAs that had positive signals in all
samples and we used data from the “expression matrix” that show miRNA expression in
relation to the relative ratio of hybridization signal for the particular miRNA being assessed
(Cy3 on the microarray) versus a sample comprising pooled RNA from all samples (Cy5 on
the microarray). Complete data from all the microarrays are provided in Supplemental Table
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1. In the expression matrix, all capture probes with both Hy3 and Hy5 signals lower than
1.5× of the median signal intensity of the given slide were excluded. With these data we
determined whether miRNAs were enriched in gray matter versus white matter using paired
Student's t tests. We also tested correlations (including R values) between the miRNA
expression levels and the densities of counted AD-type neuropathological lesions (DPs, NPs,
and NFTs), using statistical functions of Microsoft Excel™. Next we performed linear
regression-based tests of specific groups of miRNAs in comparison to the counted AD-type
pathological lesions; here, P values of the regression were determined unlike the other tests
that we just reported the correlation coefficient. Also, using the Partek Genomics Suite™,
we obtained a similarity matrix (using the Pearson coefficient algorithm) and then
hierarchically clustered this matrix to visualize the patterns of similarity of the miRNA
expression patterns across the different cases. This clustered similarity matrix was the basis
for separating the different miRNAs into groups related to their expression patterns.
Results
Cases evaluated, parameters of interest, and RNA quality
Data about individuals and various relevant clinical and pathological parameters are shown
in Table 1. Cases for this study were chosen to represent no-pathology controls and the
spectrum of early changes in AD. None of the cases had “end-stage” disease clinically (final
MMSE scores all were ≥13 and most were considerably higher), or pathologically (there
was no Braak stage VI case included). The histopathology (Fig. 1) was read in a quantitative
method as routinely performed at the University of Kentucky Alzheimer's Disease Center
[18,21]. This enabled us to correlate in a quantitative manner the AD-type pathologies (DPs,
NPs, and NFTs) with the miRNA profiling obtained from immediately adjacent tissue
samples. Note that RNA quality was poor for one sample (case 7-degraded) and marginal for
another (case 1-WM). We present the data from this sample in the Supplemental Table 1,
although we did not include this sample in downstream analyses as described below. The
rationale for not completely eliding these data is that we wanted to reveal all the data we
obtained, and the effect of RNA degradation on miRNA repertoire will be of interest to
some researchers.
Initial assessment of miRNA microarray data and Northern blots
Raw data from all the miRNA microarrays are presented in Supplemental Table 1. In order
to assess the quality of the data, we performed two separate profiling microarrays on the
same sample, months apart. Case 1 was chosen arbitrarily. These results were very
encouraging, as shown in Supplemental Fig. 1: R2 correlation coefficient for all the miRNAs
on the microarray was 0.978.
Although the results of the microarray appeared robust in a sample-to-sample comparison,
we were concerned because some of the miRNAs that were more recently annotated had
unexpectedly high apparent expression signals. However, we and others had previously
shown that some of these miRNAs are probably not actually miRNAs by a conventional
definition because their northern blot signatures fail to show the conventional “mature” ∼22
nts form and ∼70 nts pre-miRNA [25,34]. For this reason, we selected ten different miRNAs
for northern blotting that had high evident expression on the microarrays from all the
sampled microarrays. These miRNAs, along with the sequences of the probes used for
northern blotting, are shown in Fig. 2. Most of these RNA species were either not detected
(5/10) or had quite non-conventional northern blotting band patterns (5/10). Full northern
blot results are shown in Supplemental Fig. 2.
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Microarray data analyses
Since all ten candidates evaluated by northern blots did not appear to be conventional
miRNAs, we presumed that the microarray data referent to more recently annotated
miRNAs were problematic. For the sake of further clustering analyses (Figs. 3, 4, 5), we
decided to rely on the best-characterized miRNAs, which we had to delineate with arbitrary
criteria unless we performed northern blots on multiple samples for each candidate miRNA
—a practical impossibility. Our criteria for inclusion in downstream analyses and clustering
were that we only assessed the miRNAs that were expressed in all samples, and which had
an annotated number <miR-600. These criteria were adopted with the caveat that neither all
false negatives (true miRNAs excluded) nor all false positives (non-miRNAs included) were
completely eliminated. Although downstream data incorporated these criteria to narrow
further analyses, we underscore that the primary data from all the detected miRNAs are
available in Supplemental Table 1.
Using the above criteria for inclusion of miRNAs, hierarchical clustering was performed to
test how the different cases corresponded in terms of the miRNA expression patterns (Fig.
3). The result of Euclidean-based hierarchical clustering is shown, but the Pearson
coefficient-based analyses (more based on the correlation of the patterns rather than the
strength of expression) showed essentially the same pattern of clustering. Note that the
expression of miRNAs from case 7 (with degraded RNA) causes these samples to cluster
separately from the others on the heatmap. This confirms prior scholarship that miRNA
degeneration is an important consideration in miRNA profiling [32], and this is an important
caveat in our study. Aside from those samples, there was an apparent clustering between
samples derived from gray matter relative to those derived from white matter, and also cases
with more AD pathology tended to cluster together relative to no-pathology cases.
Since the clustering data indicated that we could discriminate between the miRNA repertoire
of gray matter and white matter-derived RNA samples, we sought to determine which
miRNAs were most enriched in those compartments. Paired Student's t tests were run to
evaluate the miRNAs with expression most different between gray matter and white matter.
These results are shown in Table 2. Note that some of the miRNAs we find enriched in
white matter are known to be highly expressed in oligodendrocytes [8,15,38], which is a
preliminary indication of biological relevance of our results.
We next sought to correlate the miRNA expression data seen across the different cases with
the severity of AD-type pathology that was counted in immediately adjacent tissue sections
(Table 1; Fig. 1). We queried the data for gray matter samples separately from white matter
samples, and did separate analyses for all three type of AD pathology: DPs, NPs, and NFTs.
Simple correlation coefficients were obtained comparing the miRNA expression across the
cases, relative to the pathology counts. Table 3 shows the results for the top 5 miRNAs in
each group. Note that some of the miRNAs have a positive correlation with pathology
counts, and some negative.
Prior studies have implicated a handful of miRNAs as being downregulated in AD and
which may regulate AD-related genes, including miR-15, miR-107, miR-29, and miR-128
[6,11,16,24,28,35]. MiR-15 and miR-107 belong to a collection of genes referred to as the
miR-15/107 group because of sequence similarity and overlap of function [9]. The
miR-15/107 group in humans comprises miR-15a, miR-15b, miR-16, miR-103, miR-107,
miR-195, miR-424, miR-497, and miR-503. Those expressed in our microarray are shown in
Table 4. Note that indeed multiple members of the miR-15/107 group systematically tend to
change in expression in correlation with the presence of AD-type pathology—mostly in
correlation with the numbers of counted DPs. As noted above, miR-424 is increased in white
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matter in AD apparently, in contrast to other members of the miR-15/107 group which are
downregulated in gray matter.
Since our data indicated that multiple different miRNAs were changed in correlation with
the severity of AD pathology, we sought to better understand whether there were group
patterns in miRNA expression in our dataset. To study this, a similarity matrix was created
using the Partek Genomics Suite™ software, comparing all 170 conventional miRNAs that
were included in our sample as described above. Figure 4 shows the hierarchical clustering
of the similarity matrix, assessing the conventional miRNAs in the non-degraded samples
including both gray matter and white matter. In this heatmap diagram, all the rows are
miRNAs and all the columns miRNAs, and the heatmap intensity indicates the degree of
similarity with blue being positively correlated and red being more negatively correlated.
Note that this hierarchical clustering reveals groups of miRNAs with similar expression
patterns across the different samples, and which tend to correlate negatively with other
groups of miRNAs.
At the top of Fig. 4 is a graph that shows the results of analyses of three different parameters
for each of the miRNAs in the columns below: correlation for each miRNA's expression
with the number of counted DPs across the different cases; correlation for that miRNA's
expression with the number of NFTs across the different cases; and the degree to which that
miRNA was enriched in gray matter versus white matter. The simple correlation coefficients
were calculated comparing the expression matrix values for each miRNA for each case
versus the number of pathological lesions in the same cases. The enrichment in gray matter
versus white matter shows the number of the P value of paired Student's t tests comparing
all the cases expression values in gray matter versus white matter, with positive values being
enriched in gray matter and negative in white matter.
Observation of Fig. 4 provided the basis of separating the 170 highly expressed miRNAs
into groups based on similarity of expression, relative enrichment in gray matter or white
matter, and down- or upregulation in correlation with AD pathology. Based on this pattern
in the hierarchical clustering, we designated five different groups of miRNAs (A–E based
solely on their positions in this heatmap). The characteristics of the groups, and the miRNAs
that comprise each group, are provided in Table 5. The miRNAs in Table 5 are listed in the
order in which they appeared in the similarity matrix. The most closely similarly expressed
miRNAs across all the cases are listed most closely together in the table; for example,
miR-219-5p, miR-338-3p, miR-219-2-3p, miR-338-5p had very similar expressions across
all the tissue sampled.
Discussion
Thoroughly characterized human brain samples and a state-of-the-art miRNA profiling
platform were used to assess the absolute and relative expression levels of different miRNAs
across a range of early AD pathology. These data provide the first systematic evidence of
differential white matter and gray matter changes in miRNAs in human brain, with and
without brain pathology. The number of miRNAs altered in AD was higher in gray than
white matter, but a handful of miRNAs were altered specifically in white matter. These data
indicate that while the expressions of individual miRNAs may be impactful alone, we will
not understand the aggregate impact of miRNAs until we better understand the patterns of
miRNA gene expression in human brain.
There are some limitations to our approach. For example, we dissected gray matter from
white matter tissue, which took a few minutes during which some RNA degradation could
occur. Sethi et al. [32] found that miRNAs degrade differentially postmortem and indeed we
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find that our most degraded samples (case 7) had different miRNA expression. This is an
important caveat but we feel that the benefits of having gray matter separated from white
matter, which we have pointed out before [36], far outweighs the cost in terms of RNA
degradation.
We also note that our sample size is quite small (N = 10 cases with one gray matter and one
white matter sample from each) and we only evaluated a duplicate sample from a single case
(Supplemental Fig. 1). However, that duplicate revealed an almost perfect positive
correlation (R2 ∼ 0.98), and the 20 overall samples (including gray matter and white matter)
make this one of the largest high-throughput brain profiling experiments recently reported in
the literature. Furthermore, where we could correlate our results with prior studies, our data
are very compatible with previous results. For example, miRNAs that we find enriched in
white matter are also much enriched in oligodendrocytes [8, 13, 38], as one would expect.
Further, the miRNAs that have been reported to be aberrantly expressed in AD (miR-15,
miR-103/7, and miR-29) [6, 11, 23, 27, 35] were indeed changed in the “appropriate”
direction in these new data.
Although there were similarities with our prior study where we profiled miRNAs in the
superior and middle temporal gyri, the prior study only found differential expression of one
miRNA related to AD pathology—miR-107. Here, we found a much different result:
multiple miRNAs changed expression in relation to the AD pathology. There were at least
three differences in our methods that may help explain this difference. One difference in the
current study relative to our prior microarray data [35] or RT-qPCR data [23] is that we only
used samples from females. We hypothesized that this might decrease biological variation
since males and females have some differences in neurodegenerative disease phenotypes
[2,4,7,22] and miRNA expression repertoire [37]. Further, microarray technology has
improved in the past 4 years, including the addition of many newly annotated miRNAs. This
increase in the number of annotated miRNAs comes at some expense because we found that
all ten relatively newly annotated miRNAs that we evaluated using northern blots did not
show the results expected for a conventional miRNA. These data indicate that the present
annotation of miRNAs includes some sequences that are either not miRNAs or, at best, have
molecular signatures on northern blots that are unlike conventional miRNAs. We previously
had found that miR-720, which appears highly expressed on cDNA microarray, does not
resemble other miRNAs according to a conventional northern blot on RNA isolated from
human brain [36]. These data indicate that there is a need for more basic, “descriptive” work
on human brain miRNAs. Finally, the normalization methods we used in the current study
were quite distinct from our prior microarray analyses, being dependent on Cy3/Cy5
normalization relative to pooled RNA, rather than global normalization in the prior study
[35].
One contribution of this study is to describe which miRNAs are enriched in gray matter
versus white matter. The white matter-enriched miRNAs included, as expected, miRNAs
known to be enriched in oligodendrocytes [8,15,38]. Since there are multiple cell
populations enriched in gray matter (neurons and endothelial cells, for example), it remains
to be seen exactly which of those cell populations express the specific miRNAs. It is
important to complement tissue-level work with lower-throughput methods such as in situ
hybridization [26].
These new data (in agreement with prior work) indicate that it is necessary to assess the
aggregate impact of multiple miRNAs rather than focusing exclusively on a single gene. For
example, miRNAs in the miR-15/107 gene group have overlapping lists of mRNA targets
[9,14]. It will not be adequate to merely explain the impact of (for example) miR-15a or
miR-107 because we can now see that miR-15a, miR-15b, mR-16, miR-195, miR-103, and
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miR-107 are all downregulated in AD gray matter, whereas miR-424 from this gene group is
actually upregulated in AD white matter! More work will be required in order to understand
how these aggregate neurochemical changes impact the brain.
Although each miRNA had its own unique expression signature, biological variation in
miRNA expression could be used to separate the miRNAs into five groups. These groups
had systematic tendencies in terms of enrichment in gray or white matter, and whether they
were up- or downregulated in relation to the severity of AD-type pathology. These data
should be interpreted with caution because the group designations are somewhat
tautological: much of the biological variation in our samples may relate to the presence or
absence of AD pathology.
In the future we may learn how brain miRNAs are coordinately expressed and the molecular
pathways involved in AD. A key feature of the “amyloid cascade hypothesis” [10] in AD is
that various genetic and environmental cues can lead to the deposition of amyloid plaques,
and these plaques initiate or potentiate downstream changes that culminate in neurofibrillary
pathology (NPs and NFTs), cell death, synapse elimination and, ultimately cognitive
impairment. Amidst all of that pathology it is extremely challenging to determine causality,
and to separate impactful changes from epiphenomena. For example, it has been posited that
both plaques and tangles may be at least partly adaptive responses [5], although these
alternative hypotheses should themselves be evaluated with caution [20]. Also, the
correlative impact of DPs on cognition is controversial—most but not all previous studies
indicate that DPs are not directly correlated with cognitive impairment [19,20,29]. However,
in the present study, we have at least provided new insights into the stage of AD progression
where specific miRNAs' expression seems to change, and the compartment where that
change may mostly occur. We found that relatively many different miRNAs change in the
gray matter (including miR-15/107 genes, miR-29 paralogs, miR-181a, miR-128, and other)
and the AD-related pathological subtype that most closely correlated with the miRNA
changed expression was the DPs. These ideas are presented schematically in Fig. 5. In future
studies we may be able to understand whether those miRNAs contributed to the
development of plaques, or vice versa. In any case, since AD is a human-specific condition
it is important to know about these human brain miRNA expression patterns, which may
help inform other experimental models.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.
Representative photomicrographs from the superior and middle temporal cortical gyri of
individuals sampled for the current study. Tissue sections for histopathology (Table 1) were
immediately adjacent to the tissue samples used for RNA isolation. Amyloid plaques are
stained using Aβ immunohistochemistry (IHC) as shown in a–c. Note that in cases 1 and 2
(a, b), there is no observable Aβ plaques. By contrast, case 10 (c, d, f) had the highest
densities of Alzheimer's disease (AD)-related pathology. Bielschowsky (Biel) silver stain (d)
confirms the presence in case 10 of diffuse amyloid plaques (downward arrow), neuritic
amyloid plaques (upward arrow), neurofibrillary tangles (leftward arrow), and also viable-
appearing neurons (rightward arrow). Hematoxylin and eosin (H&E) stains of both cases 1
and 10 demonstrate viable-appearing pyramidal neurons in the temporal cortex. Even in the
most severely affected AD brain evaluated in the present study, the disease had not
progressed to a stage of widespread neuronal cell death. Scale bars 100 μm (a–c) and 50 μm
(d–f)
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Fig. 2.
Northern blots were performed on ten different miRNAs with relatively high expression
according to the microarrays used in the current studies despite lack of previous evidence of
brain expression. 20 μg of RNA was isolated from human frontal cortex (Fr), cerebellum
(Cb), hippocampus CA1 (Hi), substantia nigra (SN), and superior and middle temporal gyri
(Te), and these samples were run on 15% urea-polyacrylamide gel electrophoresis.
Representative ethidium-bromide stained gel is shown in left. Results are shown for
miR-665, miR-1308, mir-551b, and miR-124 with the latter being the only one that has been
firmly documented in human brain. Note that the northern blotting staining pattern for
miR-124 is exactly as expected with a ∼22 nts band (large arrow) and a slower-migrating
∼70 nts band (smaller arrow). However, none of the other putative miRNAs stained as
expected for a conventional miRNA (see table). These results, along with prior studies,
confirm that some annotated miRNAs are not necessarily functioning as conventional
miRNAs in human brain
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Fig. 3.
Hierarchial clustering of microarray results from gray matter and white matter of all ten
brain samples evaluated in the current study. A representative photograph of gray and white
matter tissue that had been freshly dissected for this study, prior to RNA isolation, is shown
at the bottom of the figure. Each column of the heatmap figure represents a particular
microarray sample. Each row is a miRNA (total N = 170 presumed conventional miRNAs).
Heatmap coloring is based on miRNA expression levels. Both rows and columns are
hierarchically clustered according to the Euclidean (default) method. The table at the bottom
indicates which case the samples were derived from, whether the sample was gray or white
matter, and the CERAD scores that indicate the densities of Alzheimer's disease-type
neuritic amyloid plaques (B indicating moderate density of neuritic plaques and C indicating
high density of neuritic plaques). Both samples from case 7, with degraded RNA, clustered
separately from all the others. Note that among the non-degraded samples, gray matter-
derived samples cluster separately from all the white matter samples. Further, there is a
tendency of cases to cluster together that have similar CERAD scores
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Fig. 4.
Hierarchial clustering of gene expression similarity matrix that allowed us to visualize the
similarity of the patterns of miRNA expression across different cases including both gray
matter and white matter samples. In this heatmap, all the rows and columns are miRNAs
[each miRNA (N = 170, corresponding to the presumed conventional miRNAs shown in
Supplemental Table 1) occupies one column and one row] and the heatmap represents the
degree of similarity of expression for the various different miRNAs. This diagram allows us
to visualize the phenomenon that groups of miRNAs appear to have similar expression
patterns that contrast sharply with other groups of miRNAs. The chart at the top of the figure
shows how these same miRNAs are correlated with the densities of Alzheimer's disease
(AD)-type pathology [diffuse plaques (DPs) and neurofibrillary tangles (NFTs)] with
correlation being indicated by the R value of correlation across cases 1–10. The degree of
enrichment in gray matter (GM) or white matter (WM) is also charted. All these values are
available in Supplemental Table 1. Based solely on visual inspection of this diagram, we
segregated the miRNAs into five different groups (A–E) and sought to test the hypothesis
that miRNAs in the different groups may have systematically different tendencies to be
enriched in gray or white matter, and/or different correlative relationship with the density of
Alzheimer's disease-type pathological lesions
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Fig. 5.
Results indicate a shift in gray matter miRNA expression early in the pathological
progression of Alzheimer's disease (AD). It is not known what causes some individuals but
not others to have extensive diffuse amyloid deposition, or the pathogenetic that cause a
subset of those persons to progress to the later stages of AD that correlate with the presence
of neurofibrillary pathology. However, the current study indicates that many miRNA
changes occur, predominantly in gray matter, and in relatively strong correlation with the
early changes and thus may also contribute to the additional downstream pathology. Only a
handful of miRNAs, such as miR-212 and miR-454, appear to change in correlation to the
presence of neurofibrillary pathology, and these changes are seen in both white matter and
gray matter. Photomicrograph of diffuse plaques shows Ab immunohistochemistry;
neurofibrillary pathology is stained using the Gallyas silver impregnation method
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Table 5
miRNAs in Alzheimer's disease
miRNA group Gray matter or
white matter
enriched
Upregulated or
downregulated in
Alzheimer's
disease
miRNAs in group
A Gray matter Upregulated miR-519e, miR-574-5p, miR-498, miR-518a-5p/miR-527, miR-525-5p, miR-300,
miR-576-3p, miR-583, miR-146b-3p, miR-490-3p, miR-549, miR-516a-5p,
miR-510, miR-184, miR-516b, miR-298, miR-214, miR-198, miR-451, miR-144,
miR-424, let-7e
B White matter Upregulated miR-509-5p, miR-574-3p, miR-576-5p, miR-302e, miR-220b, miR-208a,
miR-215
C Gray matter Downregulated miR-485-3p, miR-381, miR-124, miR-34a, miR-129-5p, miR-29a, miR-143,
miR-136, miR-145, miR-138, miR-129-3p, miR-128, miR-379, miR-299-5p,
miR-218, miR-149, miR-135a, miR-7, miR-126, miR-411, miR-335, miR-9,
miR-378, miR-488, miR-432, miR-127-5p, miR-127-3p, miR-491-5p, miR-376c,
miR-377, miR-95, miR-222, miR-29b, miR-329, miR-495, miR-551b, miR-195,
miR-125b, miR-30b, miR-221, miR-139-5p, miR-487a, miR-487b, miR-107,
miR-146b-5p, miR-29c, miR-30a, miR-582-5p, miR-103, miR-342-3p,
miR-331-3p, miR-30c, miR-30d, miR-382, miR-22, miR-125a-5p
D White matter Downregulated miR-491-3p, miR-423-5p, miR-34b, miR-422a, miR-34c-5p, miR-584,
miR-219-5p, miR-338-3p, miR-219-2-3p, miR-338-5p, miR-181a, miR-181b,
let-7b, miR-151-3p, miR-197, miR-19a, miR-20a, miR-17, miR-106a, miR-32,
miR-340, miR-19b, miR-21, miR-151-5p, miR-194, let-7c, miR-330-3p,
miR-27b, miR-93, miR-15a, miR-339-5p, miR-193b, miR-106b, miR-16,
miR-23b, miR-15b, miR-320d, miR-320b, miR-320c, miR-320a, miR-557,
miR-33a, let-7a, miR-374b, miR-140-3p, miR-374a, miR-24, miR-140-5p,
miR-26a, miR-513a-5p, miR-212, miR-142-5p, miR-142-3p, miR-26b,
miR-520d-5p, miR-193a-3p, miR-92b, miR-330-5p, miR-186, let-7f, miR-223,
miR-412, miR-185, miR-148b, miR-101, miR-99b, miR-27a, miR-589, let-7i,
miR-361-3p, miR-361-5p, miR-423-3p, miR-190, miR-301a, miR-365, miR-23a,
miR-363, miR-326
E Gray matter Downregulated miR-425, miR-191, miR-519d, let-7g, miR-98, miR-99a, miR-30e
Five groups of miRNAs (A–E) that were shown graphically on Fig. 4. miRNAs were grouped by the similarity of gene expression as detected
across all nondegraded samples including both gray and white matter. As might be expected, some of the variability corresponded to whether the
tissue was sampled from gray matter or white matter-Group D was almost exclusively white matter-enriched miRNAs, whereas Group C was
mostly gray matter-enriched. MiRNAs that were positively correlated with the density of diffuse amyloid plaques (DPs) were in group A and B. By
contrast, the negatively correlated miRNAs were in groups C–E. The complete gene expression data is provided in Supplemental Table 1
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